Exchange: NYSE·Updated 07:30 PM EDT

RVTY News

News
all
press releases
Here's How Much You Would Have Made Owning Revvity Stock In The Last 15 Years
Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 14.61%. Currently, Revvity has a market capitalization of $16.24 billion.read more...
Benzinga
More News
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more
These are the stocks posting the largest moves midday...
CNBC: Top News
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Zacks
Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.read more...
Benzinga
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is...
Business Wire
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Zacks
What Makes Revvity (RVTY) a New Buy Stock
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Is the Options Market Predicting a Spike in Revvity Stock?
Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
Zacks

Advertisement|Remove ads.